Neurogene Inc. - 8-K Filing
Neurogene Inc. filed an 8-K on June 29, 2026 to announce positive long-term clinical data from its Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome. Across 10 participants, a total of 47 developmental milestones were gained (average of 4.7 per participant), with continued improvements observed through 30 months post-treatment and no plateau or milestone loss noted. The company also reported that the treatment was generally well-tolerated at the 1E15 vg dose. (Items: 7.01 and Exhibit 99)
Tickers: $NGNE